Description Cagrilintide is an investigational, long-acting synthetic peptide that acts as a dual amylin and calcitonin receptor agonist (DACRA), primarily under development for the treatment of obesity and type 2 diabetes
GHK-Cu, a copper-binding tripeptide first isolated from human plasma by Pickart in 1973, is one of the most thoroughly studied peptides in skin biology, with published research demonstrating its influence on collagen synthesis, antioxidant enzyme regulation, and the expression of over 4,000 human genes
However, this delayed gastric emptying can also reduce bowel motility, leading to constipation
The peptide's stability profile allows for both oral and parenteral administration, with documented biological activity through multiple delivery routes including subcutaneous, intramuscular, intraperitoneal, and oral administration